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cell carcinoma (RCC) grown on chicken embryo chorioallantoic membranes (CAM-PDX) as a model of early metastatic disease.
METHODS: Clinical grade MV-NIS was grown at Mayo Clinic facilities. Patient tumor cores were obtained from multiple independent sites of the primary tumor at the time of radical nephrectomy. Sectioned tumor fragments were implanted on chicken embryo chorioallantoic membranes and allowed to become vascularized over approximately seven days. In vivo infectivity studies were performed with measles virus expressing green fluorescent protein (MV-GFP), allowing real-time serial visualization of infection using fluorescent stereoscopy. Direct virus inoculation and intravascular administration were utilized. Volumetric Doppler US quantified xenograft vascularity as a measure of treatment response.
RESULTS: MV-GFP achieved robust infection of patientderived RCC tumors grown in the CAM model of early metastatic disease, as visualized by fluorescent stereoscopy. The kinetics and distribution of infection varied markedly between direct and intravenous administration, with direct inoculation achieving infection within 24 hours and resulting in near complete infection and xenograft destruction within four days. Intravenous administration achieved infection restricted by neovascularization of the xenograft with delayed kinetics and limited distribution compared to direct administration. Volumetric Doppler ultrasound quantified the vascularization index (percent xenograft volume composed of vasculature), correlating MV infection with decreased xenograft vascularity.
CONCLUSIONS: Our data show robust infection and destruction by oncolytic MV of patient-derived RCC xenografts grown in vivo on chicken embryo chorioallantoic membranes. Xenograft destruction was correlated with loss of vascularity as measured by volumetric Doppler ultrasound. Infection was more rapid and widespread after direct inoculation compared to intravenous administration. These data highlight the potential of oncolytic virotherapy as a therapeutic strategy against metastatic RCC. Importantly, the CAM-PDX model allows for rapid and high-throughput analysis of disease response to therapy by individual patient tumors, making in-vivo directed patient-specific treatment approaches a viable option for future oncolytic virotherapy trials. The objective of this study was to demonstrate creation of a patient derived xenograft (PDX) mouse model of RMC which could be subjected to treatment with anti-neoplastic agents.
METHODS: After institutional review board approval, severe combined immunodeficiency (SCID) mice (CB17/Icr-Prkdc/IcrIcoCrl, Charles River) were used to create PDX models. From the RMC tissue bank at our institution a patient sample was chosen for xenografts. Patient tumor samples were sliced and implanted in the SCID mouse flank under anesthesia. Short tandem repeat (STR) fingerprinting was used to confirm matching between the human and PDX tissue. The PDX mice were then exposed to various treatment agents (Table 1) . Tumors were measured weekly. Treatment continued until a measureable response was noted or tumor growth exceeded the protocol limits.
RESULTS: Two experiments of tumor implantation and treatment were completed. Each included three treatment arms and a control arm divided with equal numbers of PDX mice (N¼25 experiment 1, N¼42 experiment 2). Gemcitabine/Cisplatin dosing was reduced by one half during the first experiment due to intolerability. The remaining dosages were unchanged. After a mean treatment duration of 34.5 days, tumor shrinkage from baseline was only observed in the gemcitabine/cisplatin group, including 1/5 (20%) in experiment 1 and 3/6 (50%) in experiment 2 (figure 1) demonstrating a complete response. The other treatment arms showed a response compared to control, but maintained an increase in size from baseline CONCLUSIONS: We demonstrate the successful creation of a mouse RMC model with gemcitabine/cisplatin therapy showing excellent treatment efficacy. Further work will include result validation as well as genomic sequencing to detect predictive markers and establish novel therapeutics.
Source of Funding: None
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THE ASSOCIATION BETWEEN SARCOPENIA AND MOLECULAR SUBTYPES OF CLEAR CELL RENAL CELL CARCINOMA INTRODUCTION AND OBJECTIVES: Sarcopenia is associated with poor prognosis, while high body mass index (BMI) is associated paradoxically with improved outcomes among clear cell renal cell carcinoma (ccRCC) patients. We examined how sarcopenia was associated with molecular subtypes of ccRCC and whether the association differed by BMI.
METHODS: The cohort consisted of 76 ccRCC patients treated by nephrectomy at Memorial Sloan Kettering Cancer Center who were transcriptomically-profiled. Computed tomography scans without contrast performed within 60-days of surgery were reviewed to determine skeletal muscle cross-sectional area. Sarcopenia (yes/no) was defined according to gender-specific international consensus definitions (skeletal muscle index of < 55cm2/m2 for men and <39 cm2/m2 for women). Obesity (yes/no) was defined as pre-surgical BMI 30 kg/m2. The ClearCode34 gene expression classifier categorized patients into e958 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 
